Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Kenneth Hoberman


  • Chief Operating Officer at Stemline Therapeutics Inc (STML), 2018-01-13
  • at Tg Therapeutics Inc. (TGTX), 2017-06-19
Insider Trading: Purchases See All
Company Symbol Price Amount Relationship Remaning Holdings Date Form 4
STML $10.99 2,000 Officer 89,535 2014-09-02 Filing
Insider Trading: Sales See All
Company Symbol Price Amount Relationship Remaining Holdings Date Form 4
STML $13.93 14,040 Officer 384,792 2018-01-08 Filing
STML $14.75 40 Officer 398,832 2017-12-18 Filing
STML $14.18 11,943 Officer 398,872 2017-12-15 Filing
STML $8.16 2,342 Officer 277,674 2017-03-07 Filing
STML $7.01 4,027 Officer 279,655 2017-02-28 Filing